The work we do is guided by people living with rare and devastating diseases. We are driven to continuously innovate and create meaningful value in all we do to help patients and families fully live their best lives.
A high-level overview of Alexion Pharmaceuticals, Inc. (ALXN) stock. View (ALXN) real-time stock price, chart, news, analysis, analyst reviews and more.
Get the latest Alexion Pharmaceuticals, Inc. (ALXN) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.
Alexion Pharmaceuticals, Inc. (ALXN) 182.50 (0%)12-31 19:00 Open:181.04 High:182.67 Volume:3 Pre. Close:182.5 Low:180.21 Market Cap:0(M) Technical analysis Short term Mid term Targets6-month :1-year : ResistsFirst :Second : Pivot price ...
Sickle Cell Disease companies working in the treatment market are – BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharmaceuticals, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis Pharma, Editas Medicin, Pfizer, Emmaus Medical, Inc, Vertex Pharmaceuticals, CRISPR therapeutics, Bluebird Bio...
Moriarty and Wagner will not be making the move to Boston and will be leaving the company at the end of this month.
December 23, 2024 · 207 min read · BioSpace Editorial Staff Drug shortages FDA Confirms Lilly’s GLP-1s Are Not in Shortage, Gives Compounders Grace Period December 19, 2024 · 3 min read · Tristan Manalac Layoffs Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs ...
(eculizumab) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) in adults and children in China represents a significant expansion of the company’s global footprint in rare disease, following the acquisition ...
AstraZeneca’s recent acquisition of rare disease specialist, Alexion Pharmaceuticals, is expected to double its revenue growth through 2025 and bring greater scientific presence to immunology.
The European Commission has approved Alexion Pharmaceuticals’ Ultomiris (ravulizumab) for the treatment of some adults with the ultra-rare blood disorder paroxysmal nocturnal haemoglobinuria (PNH). The decision allows use of the drug – the first and only long-acting C5 complement inhibitor adminis...